The antioxidant effects of riluzole on the APRE-19 cell model injury-induced by t-BHP

Chaolan Shen1,2†, Wei Ma1†, Wenbin Zheng3, Hao Huang1, Renchun Xia4, Chu Li1 and Xiaobo Zhu1*

Abstract

Background: Age-related macular degeneration (AMD) causes the dysfunction of the retinal pigment epithelial (RPE) cells. In this study, we examined the effects of riluzole, a sustained activator of the TRAAK potassium channel, on human RPE (ARPE-19) cells in an oxidant-induced cell-injury model and elucidate the mechanism of riluzole on RPE cell apoptosis.

Methods: The follow four groups of ARPE-19 cells were treated with riluzole and/or tert-butyl hydroperoxide (t-BHP) for 24.0 h: control, t-BHP, riluzole, and t-BHP + riluzole. Cell apoptosis was measured by flow cytometry, and Western blotting was performed to analyze the expression of the weakly inward rectifying potassium (TRAAK) channel. Finally, the mitochondrial membrane potential (Δψm) was detected by flow cytometry, and cytochrome C (Cyt-c) release was assessed by Western blotting.

Results: The viability of the cells in the cotreated group was significantly higher (85.6 ± 3.1%) than that in the t-BHP group (66.2 ± 2.5%). In addition, the cells in the cotreated group had a higher effect on increasing the expression of TRAAK than the t-BHP group. The results also showed that Cyt-c translocation significantly decreased and Δψm increased in the cotreated group.

Conclusions: These results demonstrate that riluzole protects RPE cells from apoptosis. The protection mechanism of riluzole could be from stabilizing mitochondrial Δψm and preventing the release of Cyt-c. Changes in TRAAK expression might also contribute to the protection of RPE cells.

Keywords: Riluzole, TRAAK K2P channel, ARPE-19 cells, AMD, apoptosis

Background

Age-related macular degeneration (AMD), the loss of macular function from degenerative cellular changes caused by aging, is the leading cause of central vision loss in the elderly in developed countries [1]. Retinal pigment epithelial (RPE) cells are thought to be involved in several degenerative diseases of the retina, including AMD. In spite of the multiple pathways that contribute to RPE cell death, caspase signaling was demonstrated to be a common pathway in RPE cell apoptosis during AMD; however, caspase inhibitors only slow down apoptosis rather than inhibit it, which suggests that rescuing cells from death during the earlier stages of apoptosis might be more efficient [2, 3].

Recent studies have focused on the weakly inward rectifying potassium channel (TRAAK), a member of the two-pore domain potassium channel (K2P), which is involved in degenerative diseases of the central nervous system (CNS). Expressed predominantly in CNS, K2P has various important functions, such as transmitting synapses, maintaining the resting membrane potential, and regulating cell volume, as well as regulating in pathological processes [4]. The activity of the TRAAK K2P channel is affected by many physiological conditions, including the presence of polyunsaturated fatty acids,

* Correspondence: zhuxbo@mail.sysu.edu.cn
†Equal contributors
1The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
levels of extracellular pH, mechanical stress, and osmotic pressure [5, 6]. Opening the TRAAK channels down regulates neuron excitability and decreases the cellular metabolic rate, which plays a key role in ischemia-induced neuronal degenerative processes [7–9].

The retina is regarded as a direct extension of the CNS, and its mechanisms for degeneration and performance have many properties similar to those of CNS. Thus, it has been proposed that TRAAK K<sub>2P</sub> also plays a role in inhibiting retinal cell apoptosis, which makes TRAAK K<sub>2P</sub> a new target for treating retinal degenerative disease. It is known that 2-amino-6-trifluoromethoxy benzothiazole (riluzole) is a neuroprotective drug that activates TREK/TRAAK channels. In our previous studies, we observed that riluzole could protect hRPE cells against oxidative injury–induced cell death [10], but additional studies are needed to determine the mechanisms for this effect. In this study, we elucidate the mechanism of activated TRAAK channels on human RPE (ARPE-19) cells in an oxidant-induced cell injury model.

**Methods**

**Cell culture and treatment**

ARPE-19 cells were obtained from American Type Culture Collection (Manassas, VA, USA). This study was approved by the Ethics Committee of the Zhongshan Ophthalmic Center and followed the tenets of the Declaration of Helsinki. These cells were cultured in Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12; Invitrogen, Paisley, UK) plus 10.0% fetal bovine serum (Sijiqing, HZ, China) in a humidified incubator at 37.0 °C and 5.0% CO<sub>2</sub>. The cells were grown to an appropriate density and used at 10–15 passages.

The ARPE-19 cells were divided into four groups as follows: control, 10.0-μM riluzole (Tocris, Minneapolis, MN, USA), 300.0-μM tert-butyl hydroperoxide (t-BHP; Sigma-Aldrich, St. Louis, MO, USA), and 300.0-μM t-BHP cotreated with 10.0 μM riluzole. After reaching 80.0% confluence, the cells were incubated under different conditions for 24.0 h.

**Evaluation of apoptosis rates**

The apoptotic rates were analyzed using Flow-Count Fluospheres (Beckman Coulter, Brea, CA, USA) and an annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) kit (Roche, Penzberg, Germany) in which annexin V binds to the exposed phosphatidylserine on the plasma membrane of apoptotic cells. The cells were stained according to the manufacturer’s instructions. The percentage of early apoptosis was calculated from the proportion of cells that were annexin V–positive and PI-negative (Q4 in Fig. 1a), while the percentage of late apoptosis plus necrosis was calculated from the proportion of cells that were annexin-V and PI double positive (Q2 in Fig. 1a).

**Quantitative analysis of TRAAK expression by western blotting**

To assess TRAAK expression, ARPE-19 cells were homogenized in 100.0 μL lysis buffer containing 50.0 mM Tris–HCl (pH 7.5), 150.0 mM NaCl, 0.5% Triton X-100, and 1×

---

![Fig. 1](attachment:image.png)

**Fig. 1** Activation of two-pore domain potassium channels (K<sub>2P</sub>) improved human retinal pigment epithelia (ARPE-19)-19 cell survival. **a** Representative annexin V/PI staining of apoptosis cells in riluzole and/or t-BHP treat with ARPE-19 cells for 24.0 h. **b** Graphic representation of the survival ratios for ARPE-19. *P < .05 vs. t-BHP group. **c** Quantitative analysis of the early apoptosis ratio of ARPE-19 at 24.0 h post-treatment. *P < .05 vs. t-BHP group.
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). The samples were centrifuged at 11000 g at 4.0 °C for 30.0 min, after which the supernatants were collected and mixed with 5× sample loading buffer to prepare the samples.

Briefly, the protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred to a polyvinylidene fluoride membrane (Roche, Penzberg, Germany). The membranes were blocked in 5.0% bovine serum albumin (BSA) for 1.0 h at room temperature (RT) and incubated at 4.0 °C overnight with rabbit polyclonal anti-TRAAK antibody (1:1000; APC-108, Alomone Labs, Jerusalem, Israel). The membranes were then incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody for 1.0 h at RT. The integrated optical density of each protein was normalized to that of β-actin for quantitative comparison.

**Detection of cytochrome c release**

To verify the cytochrome C (Cyt-c) release, subcellular fractions were used to detect the Cyt-c in the cytosol and mitochondria by Western blotting [11]. The cells were suspended with buffer A (20.0 mM HEPES-KOH [pH 7.5], 10.0 mM KCl, 1.5 mM MgCl2, 1.0 mM EDTA, 1.0 mM EGTA, 1.0 mM DTT, 250.0 mM sucrose, and 1× protease inhibitor cocktail) (Sigma-Aldrich, St. Louis, MO, USA) and homogenized using a Dounce homogenizer. Cell debris and nuclei were removed by centrifugation at 10000 g for 10.0 min at 4.0 °C. The supernatant was further centrifuged at 10000 g for 20.0 min, and then transferred to clean tubes and centrifuged at 100000 g for 1.0 h at 4.0 °C. The supernatant was collected as the cytosolic fraction and the pellets were collected as the mitochondrial fraction, which was re-suspended in buffer A containing 0.5% (v/v) NP40. The cytosolic and mitochondrial fractions were mixed with 5× sample loading buffer to prepare the samples. The Western blotting protocol was followed as above with incubation of mouse monoclonal anti-Cyt-c antibody (1:1000; Cell Signaling Technology, Danvers, MA, USA). Anti β-actin (1:2000; Cell Signaling Technology, Danvers, MA, USA) and anti-COXIV antibody (1:1000, Molecular Probes, Rockford, IL, USA) were used as loading controls.

**Measurement of Δψm by JC-1**

A JC-1 fluorescent probe (Merck, Darmstadt, Germany) was used to measure Δψm, of ARPE-19. HRPEs were incubated with 1.0 μg/mL JC-1 for 15.0 min at 37.0 °C, centrifuged at 800 g for 5.0 min, washed with PBS, and analyzed immediately using a Beckman Gallios Flow Cytometer (Beckman Coulter, Brea, CA, USA). The photomultiplier settings were adjusted to detect green fluorescence (uEM = 525.0 nm) of the JC-1 monomers on filter 1, and red fluorescence (uEM = 590.0 nm) of the JC-1 J-aggregates on filter 2. The ratio of red to green (aggregate to monomer) fluorescence intensity was used to assess the ratio of healthy cells to apoptotic cells with low Δψm.

**Statistical analyses**

The data are expressed as the mean ± SD. Differences among the groups were assessed by one-way analysis of variance and the Bonferroni multiple comparison test, and all data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). \( P < .05 \) was considered statistically significant.

**Results**

**Activation of \( \text{K}_{2\text{P}} \) improved ARPE-19 cell survival**

Whether \( \text{K}_{2\text{P}} \) improved ARPE-19 cells survival should be confirmed before investigating the role of \( \text{K}_{2\text{P}} \) in ARPE-19 cells. To address this, we measured the survival ratio in ARPE-19 cells treated with t-BHP plus riluzole or t-BHP alone using annexin V and PI staining and flow cytometry. The data showed that the survival percentage of ARPE-19 significantly decreased in the t-BHP group (66.2 ± 2.5%) over that in the control group (98.1 ± 1.0%, \( P = .004, n = 3 \)) (Figs. 1a, b); however, the percentage of surviving cells significantly increased in the t-BHP + riluzole group (85.6 ± 3.1%, \( P = .011, n = 3 \)) compared with that in the t-BHP alone group (Figs. 1a, b). Furthermore, we detected the cells’ early apoptosis after t-BHP and/or riluzole treatment. The data showed that early apoptosis significantly decreased in the t-BHP + riluzole group (3.2 ± 1.7%) compared to that in the t-BHP alone group (13.7 ± 2.0%, \( P = .001, n = 3 \)) (Figs. 1a, c).

**Quantitative expression of TRAAK \( \text{K}_{2\text{P}} \) in ARPE-19 cells**

To investigate the quantitative expression of TRAAK, we examined the TRAAK protein expression in ARPE-19 cells using Western blotting. When exposing the cells to riluzole for 24.0 h, the normalized expression of TRAAK in riluzole in the single and cotreated groups was 1.0 ± 0.1 and 0.98 ± 0.1, respectively. In contrast, the expression in the vehicle and t-BHP groups decreased to 0.70 ± 0.04 and 0.61 ± 0.04, respectively. The data showed that riluzole can dramatically increase TRAAK expression (\( P = .001, n = 4 \)) (Figs. 2a, b).

**Activation of \( \text{K}_{2\text{P}} \) prevents cytochrome c release in cultured ARPE-19 cells**

As is known, Cyt-c is an apoptotic factor normally located in the mitochondria. It is also known that activation of caspases and initiation of apoptosis will stimulate Cyt-c leakage from the mitochondria into the cytoplasm [12]; therefore, we detected Cyt-c by Western blot analysis. The data showed that more Cyt-c was released from the mitochondria into the cytoplasm in the t-BHP treated ARPE-19 cells than in the vehicle cells. Moreover, the ratio of
Cyt-c in mitochondria and cytoplasm dropped from 0.97 ± 0.05 (control group) to 0.36 ± 0.01 in the t-BHP group (P < .05, n = 3); however, Cyt-c translocation decreased in the riluzole + t-BHP and riluzole groups compared with that in the t-BHP group (Figs. 3a, b). The ratio significantly increased in the riluzole (1.21 ± 0.03) and riluzole + t-BHP groups (1.06 ± 0.05), respectively. These data indicated that riluzole protects RPE cells by inhibiting Cyt-c translocation from the mitochondria into the cytoplasm.

**Activation of K₂P prevents the loss of mitochondrial Δψm**

To determine whether the mitochondria were involved in the protective effects of activated K₂P on apoptosis, Δψₘ was measured in ARPE-19 cells after treating with riluzole and/or t-BHP for 24.0 h. We found that Δψₘ significantly decreased in the t-BHP group (0.79 ± 0.04) compared with that in the vehicle group (1.82 ± 0.13, P = .001, n = 3); however, Δψₘ significantly increased in the ARPE-19 cells in the riluzole + t-BHP group (1.27 ± 0.06) over that in the t-BHP group (P = .002, n = 3) (Figs. 4a, b). These data suggested that riluzole-activated K₂P prevents Δψₘ loss during apoptosis caused by oxidative stress.

**Discussion**

RPE cells constitute a simple layer of cuboidal cells that are localized behind the photoreceptor (PR) cells. The main sites of light energy absorption are the melanin pigment granules in the RPE cells, which are most susceptible to oxidative stress in many primary and secondary AMDs [13, 14]. Injury to RPE cells from oxidative stress is considered to be one of the crucial contributors to the pathogenesis of AMD. Associations might exist among the RPE cells, retinal neurons, and TRAAK channel neuroprotection. Riluzole is a neuroprotective drug that activates TREK/TRAAK channels and is licensed for the treatment of amyotrophic lateral sclerosis and in clinical trial for spinal cord injuries [7, 8, 15]. Thus far, research on the neuroprotective effects of riluzole is ongoing; however, to our knowledge, no study on riluzole in degenerative retinopathy has been reported. In our previous study, we observed TRAAK channel protein expression in human RPE cells, which might have relevance in cell protection. Further, we selected riluzole as an activator for TRAAK K₂P to study the protective mechanism of TRAAK K₂P during oxidative injury.

Because it is difficult to obtain fresh human eyeballs, we switched our investigation to ARPE-19 cells as an alternative choice in this study. We demonstrated that riluzole-activated K₂P significantly decreased early apoptosis induced by t-BHP (Fig. 1a) in ARPE-19 cells. This
suggested that the TRAAK K\textsubscript{2P} channels participate in the protective effects on ARPE-19 cells at the early stage of apoptosis. In addition, we demonstrated that riluzole has the effect of maintaining normal cell structure during oxidative injury [10]. Previous researchers have found that the riluzole-activated TRAAK channel opposes membrane depolarization and cell excitability [16, 17]. Thus, we proposed that the protective role of riluzole against apoptosis is a result of its capability to activate TRAAK-current potency.

To evaluate the protective effects of activated K\textsubscript{2P} on mitochondrial function, $\Delta \psi \textsubscript{m}$ and the release of Cyt-c from the mitochondria into the cytoplasm were measured. Our data showed a rapid loss of $\Delta \psi \textsubscript{m}$ and a marked release of Cyt-c under oxidative injury conditions; however, the addition of riluzole prevented $\Delta \psi \textsubscript{m}$ loss and the release of Cyt-c. The loss of $\Delta \psi \textsubscript{m}$ is an initial event during oxidative stress and indicates dysfunction of the mitochondria [18, 19]. The release of Cyt-c implies a disruption of the outer mitochondrial membrane. Our study suggests that activation of K\textsubscript{2P} can attenuate the damage to mitochondrial function under oxidative stress conditions.

Another interesting discovery from this study was the upregulation of TRAAK in RPE cells when cotreated with riluzole. Using Western blotting, the mean expression of TRAAK markedly increased in the riluzole groups (Fig. 2). t-BHP treatment increases ARPE-19 apoptosis and decreases TRAAK expression, while riluzole protects ARPE-19 cells against t-BHP-induced injury and increases TRAAK expression. Activation of the TRAAK channel during the early periods of apoptosis will also oppose depolarization of the cell membrane and reduce Ca\textsuperscript{2+} influx to help protect the cells from further damage [20]. Xu et al. [21] found that TRAAK mRNA increased by 70.0% in the cortex after ischemia. Based on our current results, it is most likely that the changes in TRAAK expression are associated with apoptosis. Whether the quantity changes of TRAAK contribute to RPE cell protection is not fully understood. Further studies are required to find the exact mechanisms and interactions of the TRAAK proteins essential for the retina protection.

**Conclusions**

Our results demonstrate that the activation of K\textsubscript{2P} induced by riluzole attenuates t-BHP-induced injury to ARPE-19 cells, which contributes to stabilizing $\Delta \psi \textsubscript{m}$ and preventing the release of Cyt-c from the mitochondria. The changes in TRAAK expression might also have some relevance in cell protection. TRAAK K\textsubscript{2P} could be a new target for the treatment of retinal degeneration-related diseases.

**Abbreviations**

AMD: age-related macular degeneration; CNS: central nervous system; Cyt-c: cytochrome c; K\textsubscript{2P}: two-pore domain potassium channels; PR: photoreceptor; Riluzole: 2-amino-6-trifluoromethoxy benzothiazole; RPE: retinal pigment epithelial; RT: room temperature; t-BHP: tert-butyl hydroperoxide; TRAAK: weakly inward rectifying potassium channels; $\Delta \psi \textsubscript{m}$: mitochondrial action potential

**Acknowledgments**

Not applicable.

**Funding**

This work is supported in part by National Natural Science Foundation of China (Grant 81,271,012) and Specialized Research Fund for the Doctoral Program of Higher Education of China (20100171120097).
Availability of data and materials
All data generated or analyzed during this study are included in this published article. More details are available from the corresponding author on reasonable request.

Authors’ contributions
XZB, CLS, and WM contributed to the design of the study; CLS, HH, RCX, WBZ, and CL conducted the study; CLS and WM acquired the data; HH, WBZ, and MW prepared the manuscript; CLS drafted the manuscript; and CL, RCX, and XZB crucially revised the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
This research was performed on the ARPE-19 cell line in vitro and did not involve live human or animal subjects. The ARPE-19 cell line (ATCC®, CRL-2302™) was purchased from the American Type Culture Collection (Manassas, VA, USA). This study and all relevant experimental protocols were approved by the Medical Ethics Committee of Zhongshan Ophthalmic Center, Sun Yat-sen University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 26 July 2017 Accepted: 16 November 2017
Published online: 23 November 2017

References
1. Congdon N, O’Colmain B, Naber CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. Eye diseases prevalence research group: causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–85.
2. Zhu XB, Luo Y, Xie L, Gao Y, Ding XY, Ma HJ, Chen HY, Tang SB. Inhibition of photoreceptor apoptosis in RCS rats by caspase-9 inhibitor. Chinese Journal of Pathophysiology. 2007;23:7–11. Chinese
3. Perche O, Doly M, Ranchon-Cole I. Transient protective effect of caspase inhibitors in RCS rat. Exp Eye Res. 2008;86:519–27.
4. Cadaveira-Mosquera A, Perez M, Reboreda A, Rivas-Ramírez P, Fernández-Fernández D, Lamas JA. Expression of K2P channels in sensory and motor neurons of the autonomic nervous system. J Mol Neurosci. 2012;48:86–96.
5. Bayliss DA, Barrett PQ. Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact. Trends Pharmacol Sci. 2008;29:566–75.
6. Kténéizès O, Benoit JP, Bayliss DA, Mulkey DK. AMP-activated protein kinase inhibits TREK channels. J Physiol. 2009;587:5819–30.
7. Duprat F, Lesage F, Patel AI, Finck M, Popey G, Lazard M. The neuroprotective agent riluzole activates the two P-domain K+(+) channels TREK-1 and TRAAK. Mol Pharmacol. 2000;57:906–12.
8. Grossman RG, Felhings MG, Frankowski RF, Burau KD, Chow DS, Tator C, Teng A, Toups EG, Harrop JS, Aarabi B, Shaffrey C, Johnson MM, Harkema SJ, Boakye M, Guestr JD, Wilson JR. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma. 2014;31:239–55.
9. Ettainche M, Fillacier K, Widmann C, Heuteaux C, Lazard M. Riluzole improves functional recovery after ischemia in the rat retina. Invest Ophthalmol Vis Sci. 1999;40:729–36.
10. Shen CL, Li C, Zhu XB, Zheng WB, Xia RC. Effect of TRAAK activator riluzole on t-BHP induced injury of human retinal pigment epithelial cells. Chinese Journal of Ocular Fundus Diseases. 2013;29:400–5. Chinese
11. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 2002;51:1938–48.
12. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, Sasaki T, Elia AJ, Cheng HY, Ravagnan L, Ferri KF, Zamann Z, Wakeham A, Haken R, Yoshida H, Kong YY, Mak TW, Zühlig-Pflucker JC, Koemer G, Penninger JM. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001;410:54–9.
13. Lu L, Hackett SF, Mincey A, Lai H, Campochiaro PA. Effects of different types of oxidative stress in RPE cells. J Cell Physiol. 2006;206:119–25.
14. Pfleger SM, O’Mealey GB, Saweda LI. Mechanisms for countering oxidative stress and damage in retinal pigment epithelium. Int Rev Cell Mol Biol. 2012;298:135–77.
15. Pandya RS, Zhu H, Li W, Bowser R, Friedlander RM, Wang X. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci. 2013;70:4729–45.
16. Lotshaw DP. Biophysical, pharmacological, and functional characteristics of cloned and native mammalian two-pore domain K+ channels. Cell Biochem Biophys. 2007;47:209–56.
17. Cadaveira-Mosquera A, Ribeiro SJ, Reboreda A, Pérez M, Lamas JA. Activation of TREK currents by the neuroprotective agent riluzole in mouse sympathetic neurons. J Neurosci. 2011;31:1375–85.
18. Szlágyi G, Simon L, Koska P, Telek G, Nagy Z. Visualization of mitochondrial membrane potential and reactive oxygen species via double staining. Neurosci Lett. 2006;399:206–9.
19. Sen T, Sen N, Jana S, Khan FH, Chatterjee U, Chakrabarti S. Depolarization and cardiopulmonary depression in aged rat brain mitochondria: relationship with oxidative stress and electron transport chain activity. Neurochem Int. 2007;50:19–25.
20. Kim D. Fatty acid-sensitive two-pore domain K+ channels. Trends Pharmacol Sci. 2003;24:468–54.
21. Xu X, Pan Y, Wang X. Alterations in the expression of lipid and mechanosensitive two-pore domain potassium channel genes in rat brain following chronic cerebral ischemia. Brain Res Mol Brain Res. 2004;20:205–9.